Authors


Davit Dallakyan MD, PhD

Latest:

How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.




Farshid Dayyani, MD, PhD

Latest:

Farshid Dayyani, MD, PhD, Discusses Multidisciplinary Approach to Research on Treatment for Gastroesophageal Adenocarcinoma

A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.


Daniel Ahn, DO

Latest:

Advanced HCC: Key Takeaways

Key opinion leaders summarize essential takeaways and highlight unmet needs in the hepatocellular carcinoma treatment landscape.



Lilit Sargsyan, MD

Latest:

How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.


Joanna Roopkumar, MD

Latest:

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.


Raoul S. Concepcion, MD, FACS

Latest:

Optimization of Genetic Testing for mCRPC

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.



Leland Chung, PhD

Latest:

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.



Brett L. Ecker, MD

Latest:

The Effect of Multidisciplinary Teams for Advancing Research in NETs

Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.


Xianyan Chen, MD

Latest:

Survival of Patients With Inoperable Non–Small Cell Lung Cancer With Baseline Severe Pulmonary Dysfunction: Impacts of Thoracic Radiotherapy and Predictive Analysis for Acute Radiation Pneumonitis

Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.



A. Gabriella Wernicke, MD, MSc

Latest:

ctDNA Data in Gynecologic Cancer RT Population May Be Hypothesis-Generating

A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.


Joanna L. Langner, MS

Latest:

Evaluation and Management of Testicular Cancer After Late Relapse

The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.


Seth Felder, MD

Latest:

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.






Caroline Seymour

Latest:

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.



Hannah Clarke

Latest:

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.


Shebli Atrash, MD

Latest:

Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center

Panelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.




Lisa Adams, PA-C

Latest:

Advanced Bladder Cancer: Future Directions in Care

Closing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.


Meletios A. Dimopoulos, MD

Latest:

Meletios A. Dimopoulos, MD, on the Future of a Combination Therapy in Multiple Myeloma

Meletios A. Dimopoulos, MD, discussed the reassuring aspects and future implications of the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma.